Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer

Clinical and Experimental Medicine

Volumn 17, Issue 1, 2017, Pages 9-18

  Zhao, Yun Peng ^a   Zhou, Ping Ting ^a   Ji, Wei Ping ^b   Wang, Hao ^c   Fang, Meng ^a   Wang, Meng Meng ^a   Yin, Yue Peng ^a   Jin, Gang ^b   Gao, Chun Fang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Diagnostic model; N glycan profiling; Pancreatic cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; FUCOSE; GLYCAN; GLYCOPEPTIDASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; N GLYCAN; UNCLASSIFIED DRUG; POLYSACCHARIDE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS CANCER; PANCREATITIS; PATIENT RISK; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS; AGED; AREA UNDER THE CURVE; BLOOD; CARBOHYDRATE ANALYSIS; CASE CONTROL STUDY; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; GENETICS; GLYCOBIOLOGY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; STATISTICAL MODEL; VALIDATION STUDY;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CARBOHYDRATE SEQUENCE; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCOMICS; GLYCOSYLATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PANCREATITIS; POLYSACCHARIDES; ROC CURVE;

EID: 84951945839     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-015-0401-2     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.
3. Ueno H, Kosuge T, Matsuyama Y, et al. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.
4. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–9.
5. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.
6. Haridas D, Chakraborty S, Ponnusamy MP, et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One. 2011;6:e26839.
7. Ravindranath MH, Yesowitch P, Sumobay C, et al. Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol. 2007;3:201–14.
8. Arnold JN, Saldova R, Hamid UM, et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008;8:3284–93.
9. Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61:1–8.
10. Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the identification of glycan biomarkers for the detection of cancer. Mol Cell Proteomics. 2013;12:846–55.
11. Mechref Y, Hu Y, Garcia A, et al. Defining putative glycan cancer biomarkers by MS. Bioanalysis. 2012;4:2457–69.
12. Hua S, An HJ. Glycoscience aids in biomarker discovery. BMB Rep. 2012;45:323–30.
13. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer based total serum protein glycomics. Nat Med. 2004;10:429–34.
14. Lebrilla CB, An HJ. The prospects of glycan biomarkers for the diagnosis of diseases. Mol BioSyst. 2009;5:17–20.
15. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37:269–74.
16. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.
17. Singh S, Tang SJ, Sreenarasimhaiah J, et al. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56:2491–6.
18. Hamada S, Shimosegawa T. Biomarkers of pancreatic cancer. Pancreatology. 2011;11:14–9.
19. Smith RA, Bosonnet L, Ghaneh P, Neoptolemos JP, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226–32.
20. Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013;34:3279–92.
21. Shaw VE, Lane B, Jenkinson C, Cox T, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer. 2014;13:114.
22. Pilobello KT, Mahal LK. Lectin microarrays for glycoprotein analysis. Methods Mol Biol. 2007;385:193–203.
23. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006;126:855–67.
24. Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014;4:28.
25. Wang J, Zhou C, Zhang W, et al. An integrative strategy for quantitative analysis of the N-glycoproteome in complex biological samples. Proteome Sci. 2014;12:4.
26. Moriwaki K, Miyoshi E. Fucosylation and gastrointestinal cancer. World J Hepatol. 2010;2:151–61.
27. Pochechueva T, Jacob F, Fedier A, et al. Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Metabolites. 2012;2:913–39.
28. Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J. 2004;20:71–8.
29. Fang M, Zhao YP, Zhou FG, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010;127:148–59.
30. Zhao YP, Ruan CP, Wang H, et al. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer. 2012;118:639–50.
31. Zhao YP, Xu XY, Fang M, et al. Decreased core-fucosylation contributes to malignancy in gastric cancer. PLoS One. 2014;9:e94536.
32. Bloomston M, Bekaii-Saab TS, Kosuri K, et al. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas. 2006;33:246–9.
33. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54–61.
34. Salvini R, Bardoni A, Valli M, et al. Beta 1,3-Galactosyltransferase beta 3Gal-T5 acts on the GlcNAcbeta 1–>3Galbeta 1–>4GlcNAcbeta 1–>R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocarcinomas. J Biol Chem. 2001;276:3564–73.
35. Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ. 2015;349:g7371.
36. Tonack S, Jenkinson C, Cox T, et al. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer. 2013;108:1846–53.